



2025 ANNUAL RESULTS

ANNOUNCEMENT PRESENTATION

Human Health Holdings Limited
盈健醫療集團有限公司
01419.HK

Disclaimer

- These materials have been prepared by Human Health Holdings Limited (the “Company”) solely for information use during the Presentation and may not be taken away, copied, reproduced, transmitted, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your company, institution, firm or organization) or published, in whole or in part, for any purpose. “Presentation” means this document, any oral presentations, any question-and-answer sessions and any written material discussed or distributed during the meeting. By attending this Presentation, you are agreeing to be bound by the restrictions set out herein and to maintain absolute confidentiality regarding the information disclosed in these materials. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
- The information contained in these materials has not been independently verified. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or opinions contained herein. It is not the intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the Company’s business, financial condition, results of operations, trading position or prospects. Some of the information is still in draft form and will only be finalized at an appropriate time. The information contained in these materials should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date of the Presentation. None of the Company, nor any of their respective affiliates, directors, supervisors, officers, employees, advisers, agents or representatives, shall have any liability whatsoever (under contract or in tort, for negligence or misrepresentation, or otherwise) for any loss or damage howsoever arising from any use of these materials or their contents or otherwise arising in connection with these materials.
- Certain statements in this Presentation are forward-looking statements that are, by their nature, subject to significant risks and uncertainties and we hereby caution recipients of this Presentation that the Company’s actual performance or results may differ materially from those projected in any forward-looking statements included in this Presentation. Any statements that express, or involve discussions as to expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases, including without limitation, “will,” “expect,” “anticipate,” “estimate,” “believe,” “going forward,” “ought to,” “may,” “seek,” “should,” “would,” “shall,” “intend,” “plan,” “projection,” “could,” “vision,” “goals,” “objective,” “target,” “schedules” and “outlook”) are not historical facts, are forward-looking and may involve estimates and assumptions and are subject to risks, uncertainties and other factors some of which are difficult to predict. Accordingly, these factors could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. The forward-looking statements herein have been based on assumptions and factors concerning future events that may prove to be in incorrect, inaccurate or incomplete. Those assumptions and factors are based on information currently available to management about the Company’s businesses and industry. No assurance can be given that these expectations will prove to be correct, accurate or complete. The Company does not assume any obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that occur subsequent to such dates or otherwise.
- Region or elsewhere in the world will contain detailed information about the Company and its management as well as the financial statements of the Company. Any decision to purchase securities in an offering of securities should be made solely on the basis of the information contained in the prospectus or offering circular to be published. By attending this presentation, you acknowledge that you will be solely responsible for your own assessment of the business, financial condition, results of operations, trading and market position or prospects of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.
- Neither this Presentation nor the contents hereof constitutes, in whole or in part, an offer to sell or issue or an offer or invitation to purchase or subscribe for any securities of the Company or its holding company or any of its subsidiaries in any jurisdiction, and no part of it or them may form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto. This Presentation does not constitute
- No securities of the Company may be sold in the United States without registration with the United States Securities and Exchange Commission except pursuant to an exemption from, or in a transaction not subject to, such registration. The Company has not registered and does not intend to register or apply for the registration of any part of the offering in the United States or conduct a public offering in the United States. In Hong Kong, this Presentation must not be sent to anyone other than to “professional investors” as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules made under that Ordinance. You acknowledge and represent to the Company and their advisers that you are a professional investor, have the knowledge, experience and capability to conduct your own assessment of the Company and its shares and that you have and will conduct your own investigation with respect to the Company and its shares and have obtained or will obtain your own independent advice relating to the investment in the shares of the Company.
- In addition, no shares of the Company may be offered to the public in Hong Kong unless a prospectus in connection with the offering for sale or subscription of such shares has been authorized by The Stock Exchange of Hong Kong Limited for registration with the Registrar of Companies of Hong Kong, failing which a prospectus must not be distributed, issued or circulated in Hong Kong. Any decision to purchase shares of the Company in the offering or sale in Hong Kong or anywhere else should be made solely on the basis of the information contained in the prospectus of the Company. Your access to the information contained herein constitutes an acknowledgment by you that the information contained herein is not (a) an offering of securities of the Company to you or the public for purchase for cash or other consideration; or (b) circulated to invite offers by you or the public to purchase for cash or other consideration any securities of the Company.
- The information contained in this document may be of a price-sensitive nature and the provision of any such information shall constitute you and /or your representatives as “insiders” subject to the laws of the Hong Kong Special Administrative Region or elsewhere. Accordingly, you may not deal in, and will inform your representatives of the restriction against dealing in, any shares in the Company in breach of any applicable laws. You agree to maintain absolute confidentiality regarding the information disclosed in this document. You will be deemed to acknowledge receipt of material non-public information about the Company and its subsidiaries and you will be deemed to represent and agree (i) to maintain absolute confidentiality regarding the information contained in these materials; (ii) to be bound by the restrictions as set forth in this Presentation and to maintain absolute confidentiality regarding any information disclosed (whether written or verbal); (iii) that any use of this information by you other than in accordance with applicable law and stock exchange rules may constitute a violation of the laws or regulations, including in relation to insider dealing/trading; and (iv) that you are solely responsible for any consequences arising from any such violation.

Elevate Your Health Value • Elevate your Life



Business Overview

- 01 Results Highlights**
- 02 Steady Advancement in General Practice Segment**
- 03 Strengthened Position in Specialties Segment**
- 04 Strategic Developments in Dental Segment**
- 05 Sustained Development of Healthy Square H2**
- 06 Underpinned Partnerships and Public-Private Collaboration**

Results Highlights



Revenue

HK \$ 644.4 million



9.1%



Gross Profit

HK \$ 295.5 million

Gross Profit Margin
45.8%



Profit Attributable to Owners

HK \$ 26.3 million



8.9%



Earnings per Share

HK 6.9 cents



Steady Advancement in General Practice Segment

Serve as a stable cornerstone

Revenue increased by 3.1%

Strategic expansion

Open three new medical centres

Foster community health

Provides comprehensive and reliable primary care services to a broader population

Prudent, demand-driven growth

Raises service quality and operational efficiencies



Strengthened Position in Specialties Segment



- Solid growth of specialties segment (23.8% YoY revenue growth)
- Ongoing engagement of specialists across multiple disciplines
- Expansion of advanced service offering.



- Introduced sophisticated treatments such as LipiFlow for meibomian gland dysfunction
- Launched the 'Eye Caring for the Elderly' campaign by donating cataract surgery quotas which worth over HK\$2 million



Strategic Developments in Dental Segment



Total Revenue (including the revenue of Monarch Dental after acquisition)

67.8
Million



祐德牙醫診所
Monarch Dental Clinic

YoY revenue growth of Dental Segment

+15.9%



Enriched service mix and enhanced capacity to meet diverse patient needs

Number of dental clinics of Monarch Dental

6



Established a cross-referral system across our platform

Sustained Development of Healthy Square H2

**Specialties
Medical
Centre**



**Health
Management
Centre**



**Health Product
Retail Centre**



**Community
Pharmacy**

**Multi-functional
Area**



**Day Procedure
Centre**



Underpinned Partnerships and Public-Private Collaboration



Vital Role

- ☺ Support the community healthcare ecosystem
- ☺ Advance public health objectives





Initiatives

- ☺ Actively participate in public health initiatives



- ☺ Enhance the connectivity of the comprehensive healthcare information infrastructure





Financial Overview


- 01** Financial Highlights
- 02** Revenue Breakdown & Gross Profit Analysis
- 03** Financial Position

Financial Highlights

	For the financial year ended 30 June 2025		
	2025	2024	Increase / (Decrease)
Operating Results (HK\$ '000) 			
Revenue	644,431	590,819	53,612 9.1%
Profit attributable to the owners of the company	26,336	24,189	2,147 8.9%
Key Ratios (%) 			
Net Profit Margin	4.1%	4.1%	--

Revenue Breakdown & Gross Profit Analysis

For the financial year ended 30 June 2025



Financial Position



HKD ('000) 	30.06.2024	30.06.2025
Total Assets	1,056,373	1,071,971
Cash and Cash Equivalents & Pledged Deposits	490,604	440,931
Total Liabilities	289,707	290,222
Interest-Bearing Bank Borrowings	31,542	16,825
Gearing Ratio	4.0%	2.1%
Total Equity	766,666	781,749

Business Outlook

Strategic Business Development

Deepening Digitalisation and
Driving Operational Efficiencies

Ongoing Public-Private Partnerships
and Community Engagement

Strengthening Brand Loyalty and
Medical and Wellness Ecosystem



Deepening Digitalisation and Driving Operational Efficiencies



Basic Information (Press [F5] to view Patient Profile)

Name: 測試病人 TEST-PATIENT-1
DOB: 01/01/2001 Age: 23 Years 1 Month Sex: Female

Payment Method: Cash

Clinical Observation and Chronic Disease
Temp.: Ht: Wt: BP: 0/0mmHg P: LMP: Hxhx: 0mmHg
Chronic Diseases: Testing 3 High Diseases 3 High

History [Click / Press [Alt] [S] to Hide; Press [T] to move within the panel to view the previous & next SOAP record; Press [Space Bar] to expand or collapse the selected SOAP record.]

2024-02-07 13:30 Dr. TEST (GP) (GP) TEST-TCTR R10.1 Pain localized to upper abdomen

Epigastric pain for - Modification

- 1. Belching
- 2. Regurgitation
- 3. Vomiting
- 4. Diarrhoea
- 5. NO tea colour urine
- 6. NO abnormal bruising

GC fair

- 1. Hydration good
- 2. Abdt. tender epigastrium
- 3. no rebound nor guarding
- 4. Bowel sound ++ve

R10.1 Pain localized to upper abdomen

Drug Name

Drug Name	Q/T	T/D	Days	Instru	AdvL	Qty	Unit	Fee
PARACETAMOL TAB 300MG	T1	ADQ4H	6	IN094	DO04	12.00	TABLET	

Charge Item

Charge Item	Fee
Consultation with medicine	\$410.00
Extra Medication	\$10.00
Laboratory Tests	\$5,110.00
Retail Product	\$100.00

Current Consultation

Template: 01 URTI Save as Template Clear all SOAP

SOAP

Prescriptions

Change Items

Medical Record

☒ NIDA
☐ GEPD

Allergy Warning

Primary Diagnosis M54.5 Low back pain
Other Diagnosis J06 Acute upper respiratory infections of multiple and unspecified sites
Printed Diagnosis Low back pain

- ✓ **Launching Core Systems**
 - Integrated Clinical Operating System
 - Omnichannel Platform
- ✓ **Advancing Key Capabilities**
 - Data Management
 - Customer Engagement
 - Tele-health Services
- ✓ **Achieving Our Goals**
 - Optimise resource utilisation
 - Improve clinical coordination
 - Deliver consistent and high-quality care

Ongoing Public-Private Partnerships and Community Engagement



Deepening collaborations with Hong Kong Government

Lead public health programs
Integrate with the government comprehensive healthcare information infrastructure



Upholding Our Mission

Operate with unwavering ethical conduct
Advance environmental stewardship
Engage actively in community health



Achieving Our Ultimate Commitment

Champion strong corporate governance
Ensure responsible business practices
Create positive, enduring impacts on our communities




Strengthening Brand Loyalty and Medical and Wellness Ecosystem

Strengthening brand engagement

Drive engaging through E-shop membership and H2 Rewards App



Build deeper customers relationships and increase repeat patronage



Expanding our medical and wellness ecosystem

Collaboration with strategic partners and the Government

Leverage Healthy Square to drive sustainable growth and market leadership





Thank You

Human Health Holdings Limited
盈健醫療集團有限公司
01419.HK